Cervical Cancer Trial Results
Second HPV Vaccine Shows Early Positive Results
(Posted: 07/17/2007, Updated: 12/02/2011) - The vaccine Cervarix® was 90 percent effective against two types of human papillomavirus (HPV) that can cause cervical cancer, according to the June 30, 2007, Lancet.
Treatment Regimen Extends Survival for Women with Cervical Cancer
(Posted: 06/29/2009, Updated: 10/20/2011) - Patients with locally advanced cervical cancer who received gemcitabine (Gemzar®) both as part of initial treatment and as part of therapy following primary treatment had improved survival compared with patients whose treatment did not include gemcitabine, according to findings presented at the 2009 ASCO meeting in Orlando.
Incomplete Excision a Risk for Those With Precancerous Cervical Intraepithelial Neoplasia (CIN)
(Posted: 12/10/2007) - A precancerous condition known as cervical intraepithelial neoplasia (CIN) is more likely to come back after surgery to remove the abnormal cells if the cells aren't completely removed, according to the November 2007 Lancet Oncology.
HPV Vaccine Not Effective for Treating Pre-Existing Infections
(Posted: 08/28/2007) - A vaccine developed to prevent infection with human papillomaviruses (HPV), the cause of cervical cancer, was found to be ineffective for treating women with pre-existing HPV infections, according to a study published in the August 15, 2007, Journal of the American Medical Association.
Long-Term Data Support Cisplatin-Based Chemoradiation for Cervical Cancer
(Posted: 05/29/2007) - Women with cervical cancer that had spread locally or regionally who received the chemotherapy drug cisplatin in addition to radiation therapy lived significantly longer than women who received a different kind of chemoradiation, according to the July 1, 2007, Journal of Clinical Oncology.
(Posted: 07/17/2007, Updated: 12/02/2011) - The vaccine Cervarix® was 90 percent effective against two types of human papillomavirus (HPV) that can cause cervical cancer, according to the June 30, 2007, Lancet.
Treatment Regimen Extends Survival for Women with Cervical Cancer
(Posted: 06/29/2009, Updated: 10/20/2011) - Patients with locally advanced cervical cancer who received gemcitabine (Gemzar®) both as part of initial treatment and as part of therapy following primary treatment had improved survival compared with patients whose treatment did not include gemcitabine, according to findings presented at the 2009 ASCO meeting in Orlando.
Incomplete Excision a Risk for Those With Precancerous Cervical Intraepithelial Neoplasia (CIN)
(Posted: 12/10/2007) - A precancerous condition known as cervical intraepithelial neoplasia (CIN) is more likely to come back after surgery to remove the abnormal cells if the cells aren't completely removed, according to the November 2007 Lancet Oncology.
HPV Vaccine Not Effective for Treating Pre-Existing Infections
(Posted: 08/28/2007) - A vaccine developed to prevent infection with human papillomaviruses (HPV), the cause of cervical cancer, was found to be ineffective for treating women with pre-existing HPV infections, according to a study published in the August 15, 2007, Journal of the American Medical Association.
Long-Term Data Support Cisplatin-Based Chemoradiation for Cervical Cancer
(Posted: 05/29/2007) - Women with cervical cancer that had spread locally or regionally who received the chemotherapy drug cisplatin in addition to radiation therapy lived significantly longer than women who received a different kind of chemoradiation, according to the July 1, 2007, Journal of Clinical Oncology.
